AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03695679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive computer-based intervention
Description: There are 4 components of the Interactive computer-based intervention(ICBI) which will be delivered in 3 phases:~1. Perceived Susceptibility and Perceived Severity~2. Perceived Benefits and Perceived Barriers~3. Cue to Action~4. Self-Efficacy~In addition, a discussion forum will be created to handle questions from the participants. Also, there will be an email address for enquiries if the participants need any support or if they want to seek further enquiry/ clarification after reading the web-based information.
Study NCT03879655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTS-270
Description: Administered IT via LP infusion of VTS-270
Study NCT00142818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 150 mg daily for males; 100 mg daily for females
Study NCT02785107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-PAC Group
Description: Participants attended a workshop, completed a worksheet and received a booster phone call follow-up at week four.
Study NCT01326416 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-Leucine and L-arginine
Description: Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
Study NCT00142818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 400 mg daily
Study NCT00142818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg and/or 100-150 mg placebo pills
Study NCT00606021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
Study NCT00606021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
Study NCT00606021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
Study NCT02752178 — intervention group
Intervention type: OTHER
Intervention: MA
Description: Monoaminergic antidepressant use
Study NCT02752178 — intervention group
Intervention type: OTHER
Intervention: DEP
Description: Depression measured using the Hamilton Depression (HAM-D) questionnaire
Study NCT01183611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental recombinant hepatitis B vaccine, HBIG
Description: Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG
Study NCT01183611 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator hepatitis B vaccine
Description: Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG
Study NCT01183611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental recombinant hepatitis B vaccine
Description: Experimental 10mcg/0.5 ml of recombinant hepatitis B vaccine
Study NCT01183611 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator recombinant hepatitis B vaccine.
Description: Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
Study NCT01183611 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator recombinant hepatitis B vaccine
Description: Placebo Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
Study NCT00868738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
Study NCT00868738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
Study NCT02527031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECMO Insertion on pre hospital setting
Description: ECMO Insertion on pre hospital setting
Study NCT02527031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In Hospital ECMO
Description: ECMO Insertion on in hospital setting for a refractory cardiac arrest
Study NCT04498949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UP
Description: The unified protocol modules are as follows:~Module 1: Setting the treatment goals and motivation augmentation Module 2: Using psychoeducation to learn the function of emotions and their development Module 3: Mindful (present-focused and non-judgmental) emotional awareness- Core module Module 4: Cognitive flexibility- Core module Module 5: Identifying and countering emotional avoidance behaviors- core module Module 6: Increasing awareness and confronting physical sensations/ interoceptive sensitivity- core module Module 7: Both situational and interoceptive emotion-focused exposures- Core module Module 8: Recognizing accomplishments and looking to the future (relapse prevention)
Study NCT04498949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Diagnostic test. Psychoeducation Supoortive care
Study NCT03513575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: no intervention
Description: Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink without any intervention.
Study NCT03513575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2: tap water gargle
Description: The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
Study NCT03513575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 3: 0.2% Chlorhexidine
Description: The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
Study NCT03513575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 4: Fluoridated tooth paste
Description: The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.
Study NCT03513575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 5: Polyol containing gum
Description: The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.
Study NCT03513575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 6: 1% sodium bicarbonate solution
Description: The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
Study NCT03646812 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 1
Description: Glucose contains 50g of available carbohydrates
Study NCT03646812 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 2
Description: Glucose contains 50g of available carbohydrates
Study NCT03646812 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 3
Description: Glucose contains 50g of available carbohydrates
Study NCT03646812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semolina Penne
Description: Semolina Penne contains 50g of available carbohydrates
Study NCT03646812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain Penne
Description: Wholegrain Penne contains 50g of available carbohydrates
Study NCT02631733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02962024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Study NCT02962024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Study NCT01374152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive sensory motor training therapy
Description: training method that emphasis on cognition/ sensation/ and motor movement together train every working day 45 minutes per day for 4 weeks.
Study NCT01763307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RECONVAL CREAM
Study NCT01763307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Study NCT03450811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernia repair
Description: Lichtenstein procedure or laparoscopic method (Total extraperitoneal) inguinal hernia repair
Study NCT00428714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: Administered orally
Study NCT01404338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Halobetasol 0.05% ointment
Study NCT01404338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ointment
Study NCT00507767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO or via PEG tube
Study NCT00507767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00507767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02363049 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colectomy
Study NCT02363049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study NCT02363049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Study NCT03646812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semolina Spaghetti
Description: Semolina Spaghetti contains 50g of available carbohydrates
Study NCT03646812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain Spaghetti
Description: Wholegrain Spaghetti contains 50g of available carbohydrates
Study NCT03646812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jasmine Rice
Description: Jasmine Rice contains 50g of available carbohydrates
Study NCT03646812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asian Noodles
Description: Asian Noodles contains 50g of available carbohydrates
Study NCT02631733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT00456599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
Study NCT00456599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
Study NCT00456599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
Study NCT01182974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: 1 gr of paracetamol PO/PZ/PR
Study NCT01182974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dypirone
Description: 1 gr PO/PZ/PR/IM
Study NCT03453255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: chidamide, decitabine, homoharringtonine, cytarabine
Study NCT02096666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 337
Description: Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
Study NCT02024880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protective catheter group
Description: The tip of this catheter is protected on insertion of the catheter.
Study NCT02024880 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional catheter group
Description: A standard embryo catheter
Study NCT01488292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECAP social skills and reading program
Description: weekly individual and group sessions
Study NCT01192503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rasagiline
Description: 1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks
Study NCT01192503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (sugar pill)
Description: 1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
Study NCT02120170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colon polypectomy
Study NCT03876691 — intervention group
Intervention type: OTHER
Intervention: Patients
Description: Patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a do-not-resuscitate.
Study NCT03876691 — intervention group
Intervention type: OTHER
Intervention: Physician
Description: The current emergency medical department departments within the preparation of the attending physician
Study NCT03452904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Description: Treatment of in suit coronary lesions with drug-coated balloon
Study NCT03452904 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-eluting stent
Description: Treatment of in suit coronary lesions with drug-eluting balloon
Study NCT04338633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional calcium hydroxide paste
Description: Conventional calcium hydroxide paste (Ultracal) will be removed in second visit.
Study NCT04338633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide nanoparticle
Description: Calcium hydroxide nanoparticle. manufactured in NanoTech. institute, will be removed in second visit.
Study NCT04338633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Calcium hydroxide with silver nanoparticle
Description: Combined Calcium hydroxide with silver nanoparticle will be removed in second visit.
Study NCT03263468 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Same sitting PCI with complete revascularization
Description: revascualrization of the non IRA (infarct related artery) of > 2.0 mm by coronary angioplasty/stenting at the time of primary PCI
Study NCT03263468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged PCI with complete revsacularization >48 hours pf primary PCI
Description: revascualrization of the non IRA (infarct related artery) of > 2.0 mm by coronary angioplasty/stenting >48 hours to 45 days post primary PCI
Study NCT04316806 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic (dietary supplement) administrated once daily (u.i.d) for 8 weeks (3 billion cfus per day)
Study NCT04316806 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rifaximin
Description: Antibiotic rifaximin consisting 400 mg capsules administrated twice daily (b.i.d) for 1week.
Study NCT04128982 — intervention group
Intervention type: PROCEDURE
Intervention: mobilization of the larynx
Description: Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression in 2 groups: patient in dorsal decubitus or Rapid Airway Management Positioner.
Study NCT01332188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.05%
Description: 1 drop in each eye at 3 separate times during a 21 day period
Study NCT01332188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.1%
Description: 1 drop in each eye at 3 separate times during a 21 day period
Study NCT01332188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24%
Description: 1 drop in each eye at 3 separate times during a 21 day period
Study NCT00769938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI (percutaneous coronary intervention)
Description: only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
Study NCT01326416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Reconditioning by a trainer
Description: Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
Study NCT03016975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards Cardioband System
Description: Transcatheter mitral valve repair with the Edwards Cardioband System
Study NCT03967964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone 2.2 g
Description: Vaginal ring with 2.2 grams DHEA.
Study NCT03967964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone 1.5 g/Testosterone 25 mg
Description: Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.
Study NCT03967964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Vaginal ring with 35 mg testosterone.
Study NCT03967964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Topical Gel
Description: Gel containing 1% testosterone.
Study NCT03967964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone Oral Capsule
Description: Capsule containing 25 mg DHEA
Study NCT00967798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
Study NCT00967798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
Study NCT03182829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DOAC Dipstick
Description: Patients collect a sample of urine for analysis.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. \[Epub ahead of print\]
Study NCT01994460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Study NCT01994460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Study NCT03016975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline Directed Medical Therapy
Description: GDMT Only
Study NCT03016975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guideline Directed Medical Therapy
Description: GDMT Only
Study NCT00633243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Directly Observed Therapy (mDOT)
Study NCT00633243 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered Therapy (SAT)
Study NCT02042456 — intervention group
Intervention type: DEVICE
Intervention: Digital Breast Tomosynthesis
Description: digital breast tomosynthesis technology
Study NCT02042456 — intervention group
Intervention type: DEVICE
Intervention: Automated Whole Breast Ultrasound
Description: Automated Whole Breast Ultrasound
Study NCT03547167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose